Contributions
Abstract: PB2390
Type: Publication Only
Background
About10% of patients with chronic myeloid leukemia(CML) treated with thyrosine kinase inhibitor(TKI) show side effects.
Aims
Aim of this study is to evaluate the side effects management expense in patients receiving imatinib or dasatinib.
Methods
This study is a retrospective multicentric study. 13patients, M/F:8/5,median age75(R60-78) received imatinib 400mg/day and 15patients, M/F:9/6,median age68(R50-72) received dasatinib100mg/day. During an observation period of 7years 3imatinib patients showed 1acute heart failure and hepatotoxicityG4,1chronic diarrheaG3, 1acute recurrent abdominal painG4 and 3dasatinib patient showed 1osteomuscular painG4, 1gastrointestinal bleedingG4, 1pleural effusion.
For each patient, the overall cost of side effects management during the entire follow-up period was calculated. This cost was then divided by the days of hospital admission, in order to give an average daily patient treatment cost. Then in each group the median of average daily costs was performed. Cost for each diagnostic and therapeutic intervention was considered in conformity of Italian National Health Service.
Results
In imatinib group the median days of hospitalization were30(R7-60), with a median daily expense of366€(R330-461),a median complication management cost of€10980and a median hospitalization cost for each patient of€22500. In dasatinib group the median days of hospitalization were15(R3-30), with a median daily expense of275€(R195-370),a median complication management cost of€4125and a median hospitalization cost for each patient of€11250.
For each patient the median saving in dasatinib side effect management respect to imatinib group is €11250for hospitalization and €6855for complication management. In dasatinib group the saving is about €90/day.
All imatinib patient with side effects changed therapy with a IInd generation TKI with an increase in follow-up test expense of about€13/day for the first 6months.
Conclusion
Management of side effects of dasatinib seems to be cheaper than imatinib. These data need confirmation on a larger cohort of patients.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Cost analysis, imatinib, Side effects
Abstract: PB2390
Type: Publication Only
Background
About10% of patients with chronic myeloid leukemia(CML) treated with thyrosine kinase inhibitor(TKI) show side effects.
Aims
Aim of this study is to evaluate the side effects management expense in patients receiving imatinib or dasatinib.
Methods
This study is a retrospective multicentric study. 13patients, M/F:8/5,median age75(R60-78) received imatinib 400mg/day and 15patients, M/F:9/6,median age68(R50-72) received dasatinib100mg/day. During an observation period of 7years 3imatinib patients showed 1acute heart failure and hepatotoxicityG4,1chronic diarrheaG3, 1acute recurrent abdominal painG4 and 3dasatinib patient showed 1osteomuscular painG4, 1gastrointestinal bleedingG4, 1pleural effusion.
For each patient, the overall cost of side effects management during the entire follow-up period was calculated. This cost was then divided by the days of hospital admission, in order to give an average daily patient treatment cost. Then in each group the median of average daily costs was performed. Cost for each diagnostic and therapeutic intervention was considered in conformity of Italian National Health Service.
Results
In imatinib group the median days of hospitalization were30(R7-60), with a median daily expense of366€(R330-461),a median complication management cost of€10980and a median hospitalization cost for each patient of€22500. In dasatinib group the median days of hospitalization were15(R3-30), with a median daily expense of275€(R195-370),a median complication management cost of€4125and a median hospitalization cost for each patient of€11250.
For each patient the median saving in dasatinib side effect management respect to imatinib group is €11250for hospitalization and €6855for complication management. In dasatinib group the saving is about €90/day.
All imatinib patient with side effects changed therapy with a IInd generation TKI with an increase in follow-up test expense of about€13/day for the first 6months.
Conclusion
Management of side effects of dasatinib seems to be cheaper than imatinib. These data need confirmation on a larger cohort of patients.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Cost analysis, imatinib, Side effects